NEWS
-
2026/04/09 Correctseq
In a breakthrough for gene therapy, the international academic journal Nature has published a landmark clinical study detailing the successful use of a novel base-editing drug to treat β-thalassemia.J
-
2025/12/01 Correctseq
CorrectSequence Therapeutics to Participate in the 67th ASH Annual Meeting
December 1, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases,
-
2025/11/07 Correctseq
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
Shanghai, China, November 6, 2025 — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successfully completed dosing and been discharged from the hospital.
-
2025/09/12 Correctseq
ShanghaiTech Scientists Take Major Step Forward in High-precision Mitochondrial DNA Editing
A research team led by Assistant Professor Yang Bei at the School of Life Science and Technology (SLST) and Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and Professor Chen Jia at SLST, ShanghaiTech University, has achieved a significant progress in mitochondrial DNA (mtDNA) editing.
-
2025/05/23 China Daily
China Daily | Chinese treatment cures Pakistani girl
A 4-year-old Pakistani girl with severe thalassemia has been successfully treated with a Chinese-developed gene-editing drug, marking the first time the technology has been used on a foreign minor, according to the Children's Hospital of Fudan University in Shanghai.
-
2025/03/27 Correctseq
Precise and Efficient RNA Editing by Cleaving ADAR Inhibitor
Recently, a collaborative team led by Professor Chen Jia from the School of Life Science and Technology (SLST) at ShanghaiTech University and Professor Yang Li at Fudan University published a study titled “Specific and Efficient RNA A-to-I Editing through Cleavage of an ADAR Inhibitor”in Nature Biotechnology.
-
2025/03/27 Correctseq
An Efficient and Precise Mitochondrial Adenine Base Editor
Mitochondria, the “powerhouses” of cells, play a vital role in adenosine triphosphate (ATP) production. Mitochondria possess their own independent DNA, termed mitochondrial DNA (mtDNA), which encodes
-
2023/11/24 Correctseq
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that the company and the research teams from ShanghaiTech University, Wuhan University, Fudan University and Children's Hospital of Fudan University published an article entitled “Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs” in Cell Stem Cell on November 20th, 2023, reporting a novel base editing strategy for treating β-hemoglobinopathies with transformer base editor (tBE).